» Articles » PMID: 21515373

Retromer Disruption Promotes Amyloidogenic APP Processing

Overview
Journal Neurobiol Dis
Specialty Neurology
Date 2011 Apr 26
PMID 21515373
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Retromer deficiency has been implicated in sporadic AD and animals deficient in retromer components exhibit pronounced neurodegeneration. Because retromer performs retrograde transport from the endosome to the Golgi apparatus and neuronal Aβ is found in late endosomal compartments, we speculated that retromer malfunction might enhance amyloidogenic APP processing by promoting interactions between APP and secretase enzymes in late endosomes. We have evaluated changes in amyloid precursor protein (APP) processing and trafficking as a result of disrupted retromer activity by knockdown of Vps35, a vacuolar sorting protein that is an essential component of the retromer complex. Knocking down retromer activity produced no change in the quantity or cellular distribution of total cellular APP and had no affect on internalization of cell-surface APP. Retromer deficiency did, however, increase the ratio of secreted Aβ42:Aβ40 in HEK-293 cells over-expressing APP695, due primarily to a decrease in Aβ40 secretion. Recent studies suggest that the retromer-trafficked protein, Wntless, is secreted at the synapse in exosome vesicles and that these same vesicles contain Aβ. We therefore hypothesized that retromer deficiency may be associated with altered exosomal secretion of APP and/or secretase fragments. Holo-APP, Presenilin and APP C-terminal fragments were detected in exosomal vesicles secreted from HEK-293 cells. Levels of total APP C-terminal fragments were significantly increased in exosomes secreted by retromer deficient cells. These data suggest that reduced retromer activity can mimic the effects of familial AD Presenilin mutations on APP processing and promote export of amyloidogenic APP derivatives.

Citing Articles

γ-secretase facilitates retromer-mediated retrograde transport.

Takeo Y, Crite M, Mehmood K, DiMaio D J Cell Sci. 2025; 138(4).

PMID: 39865938 PMC: 11883284. DOI: 10.1242/jcs.263538.


Exploring Therapeutic Strategies: The Relationship between Metabolic Disorders and FOXO Signalling in Alzheimer's Disease.

Kaur P, Khan H, Grewal A, Dua K, Singh S, Gupta G CNS Neurol Disord Drug Targets. 2024; 24(3):196-207.

PMID: 39473249 DOI: 10.2174/0118715273321002240919102841.


γ-secretase facilitates retromer-mediated retrograde transport.

Takeo Y, Crite M, DiMaio D bioRxiv. 2024; .

PMID: 38895404 PMC: 11185792. DOI: 10.1101/2024.06.07.597932.


Apolipoprotein E2 Expression Alters Endosomal Pathways in a Mouse Model With Increased Brain Exosome Levels During Aging.

Peng K, Liemisa B, Pasato J, DAcunzo P, Pawlik M, Heguy A Traffic. 2024; 25(5):e12937.

PMID: 38777335 PMC: 11141728. DOI: 10.1111/tra.12937.


Towards a Unitary Hypothesis of Alzheimer's Disease Pathogenesis.

Area-Gomez E, Schon E J Alzheimers Dis. 2024; 98(4):1243-1275.

PMID: 38578892 PMC: 11091651. DOI: 10.3233/JAD-231318.


References
1.
Borchelt D, Thinakaran G, Eckman C, Lee M, Davenport F, Ratovitsky T . Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996; 17(5):1005-13. DOI: 10.1016/s0896-6273(00)80230-5. View

2.
Aharon A, Tamari T, Brenner B . Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost. 2008; 100(5):878-85. DOI: 10.1160/th07-11-0691. View

3.
Jacobsen L, Madsen P, Nielsen M, Geraerts W, Gliemann J, Smit A . The sorLA cytoplasmic domain interacts with GGA1 and -2 and defines minimum requirements for GGA binding. FEBS Lett. 2002; 511(1-3):155-8. DOI: 10.1016/s0014-5793(01)03299-9. View

4.
Mathias R, Lim J, Ji H, Simpson R . Isolation of extracellular membranous vesicles for proteomic analysis. Methods Mol Biol. 2009; 528:227-42. DOI: 10.1007/978-1-60327-310-7_16. View

5.
Troncoso J, Cataldo A, Nixon R, Barnett J, Lee M, Checler F . Neuropathology of preclinical and clinical late-onset Alzheimer's disease. Ann Neurol. 1998; 43(5):673-6. DOI: 10.1002/ana.410430519. View